A Prognostic Survival Model of Pancreatic Adenocarcinoma Based on Metabolism-Related Gene Expression.

gene expression metabolism pancreatic adenocarcinoma prognostic survival model

Journal

Frontiers in genetics
ISSN: 1664-8021
Titre abrégé: Front Genet
Pays: Switzerland
ID NLM: 101560621

Informations de publication

Date de publication:
2022
Historique:
received: 03 12 2021
accepted: 22 03 2022
entrez: 6 6 2022
pubmed: 7 6 2022
medline: 7 6 2022
Statut: epublish

Résumé

Accurately predicting the survival prospects of patients suffering from pancreatic adenocarcinoma (PAAD) is challenging. In this study, we analyzed RNA matrices of 182 subjects with PAAD based on public datasets obtained from The Cancer Genome Atlas (TCGA) as training datasets and those of 63 subjects obtained from the Gene Expression Omnibus (GEO) database as the validation dataset. Genes regulating the metabolism of PAAD cells correlated with survival were identified. Furthermore, LASSO Cox regression analyses were conducted to identify six genes (

Identifiants

pubmed: 35664305
doi: 10.3389/fgene.2022.804190
pii: 804190
pmc: PMC9158121
doi:

Types de publication

Journal Article

Langues

eng

Pagination

804190

Informations de copyright

Copyright © 2022 Xie, Huang, Fang, Liang, Hao, Zhang, Xie, Wang, Tan and Zeng.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Lung Cancer. 2011 Feb;71(2):186-90
pubmed: 20570389
Biol Reprod. 2008 Jan;78(1):68-76
pubmed: 17928629
Hepatology. 2020 Jun;71(6):2033-2049
pubmed: 31578733
Methods Mol Biol. 2019;1882:221-228
pubmed: 30378058
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3919-24
pubmed: 23407165
Hepatogastroenterology. 2008 Nov-Dec;55(88):2016-27
pubmed: 19260470
Nat Rev Cancer. 2016 Nov;16(11):749
pubmed: 28704361
Cancer Res. 2012 Oct 1;72(19):5119-29
pubmed: 23002211
Arch Surg. 1999 Mar;134(3):245-51
pubmed: 10088562
J Exp Clin Cancer Res. 2021 Apr 8;40(1):124
pubmed: 33832516
Oncotarget. 2016 Aug 16;7(33):52993-53004
pubmed: 27367029
Int J Biochem Cell Biol. 2013 May;45(5):979-86
pubmed: 23416112
Cancers (Basel). 2019 Dec 18;12(1):
pubmed: 31861288
J Cell Biochem. 2011 Apr;112(4):1066-75
pubmed: 21308735
Cancer Res. 2021 Aug 1;81(15):4054-4065
pubmed: 34117030
Tumour Biol. 2012 Oct;33(5):1727-32
pubmed: 22678977
Front Oncol. 2018 Dec 12;8:617
pubmed: 30631752
Front Oncol. 2020 Sep 29;10:572722
pubmed: 33117704
Clin Cancer Res. 2014 Aug 15;20(16):4370-80
pubmed: 24947925
BMC Cancer. 2018 Jun 4;18(1):631
pubmed: 29866054
Eur J Cancer. 2009 Mar;45(4):648-55
pubmed: 19112016
Clin Cancer Res. 2005 Jun 15;11(12):4372-81
pubmed: 15958620
Gynecol Oncol. 2012 Feb;124(2):311-8
pubmed: 22044687
Oncogene. 2020 Apr;39(15):3179-3194
pubmed: 32060421
Am J Cancer Res. 2019 Jun 01;9(6):1145-1160
pubmed: 31285948
Nature. 2008 Apr 3;452(7187):646-9
pubmed: 18344980
Nat Rev Gastroenterol Hepatol. 2021 Jul;18(7):457-468
pubmed: 34099908
Cancer Discov. 2021 Mar;11(3):660-677
pubmed: 34009137
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Clin Pathol. 2006 Sep;59(9):965-71
pubmed: 16935971
PLoS One. 2015 Oct 13;10(10):e0140492
pubmed: 26460485
Prostate. 2017 Jan;77(1):10-21
pubmed: 27550065
Life Sci. 2011 Apr 11;88(15-16):693-700
pubmed: 21324324
Arch Biochem Biophys. 2013 May;533(1-2):11-7
pubmed: 23474458
Cancer Res. 2001 Sep 1;61(17):6548-54
pubmed: 11522653
Gene. 2019 Apr 15;692:1-8
pubmed: 30641222
Oncogenesis. 2017 Sep 25;6(9):e382
pubmed: 28945217
Nature. 2013 May 30;497(7451):633-7
pubmed: 23665962
Cancer Biomark. 2021;30(4):355-363
pubmed: 33361582
Sci Rep. 2017 Aug 11;7(1):7950
pubmed: 28801576
FEBS Lett. 2014 Aug 25;588(17):3240-50
pubmed: 25019574
Int J Oncol. 2007 Apr;30(4):849-55
pubmed: 17332923
Cancer Cell Int. 2021 Sep 8;21(1):475
pubmed: 34496841
J Exp Clin Cancer Res. 2016 Mar 16;35:48
pubmed: 26980435
Clin Chim Acta. 2005 Nov;361(1-2):135-40
pubmed: 15996648
Neoplasia. 2021 Nov;23(11):1147-1165
pubmed: 34706306
Free Radic Biol Med. 2019 Aug 1;139:70-79
pubmed: 31103463
Mol Cancer. 2020 Mar 2;19(1):50
pubmed: 32122374

Auteurs

Lin-Ying Xie (LY)

Bethune Institute of Epigenetic Medicine, The First Hospital of Jilin University, Changchun, China.

Han-Ying Huang (HY)

State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.

Tian Fang (T)

Cancer Center, The First Hospital of Jilin University, Changchun, China.

Jia-Ying Liang (JY)

Cancer Center, The First Hospital of Jilin University, Changchun, China.

Yu-Lei Hao (YL)

Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China.

Xue-Jiao Zhang (XJ)

Department of Endocrinology, China-Japan Union Hospital of Jilin University, Changchun, China.

Yi-Xin Xie (YX)

Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, China.

Chang Wang (C)

Cancer Center, The First Hospital of Jilin University, Changchun, China.

Ye-Hui Tan (YH)

Cancer Center, The First Hospital of Jilin University, Changchun, China.

Lei Zeng (L)

Bethune Institute of Epigenetic Medicine, The First Hospital of Jilin University, Changchun, China.

Classifications MeSH